Advancements in Laboratory Biomarker Discovery for Early Detection of Chronic Kidney Disease

Abdulwahab Hassan Abdullah Alshahrani[1], Abdullah Zaher Awwadh Alharthi[2], Khaled Fahad Ail Albahouth[3], Nawaf Jaber Abdullah Aljaber[4], Omar Ali Jaber Asiri[5], Abdullah Omar Mohammed Omair[6], Alharthi, Ahmed Saad O[7], Mohammed Fulayyih Faleh Alharbi[8], Sultan Hulayyil Nahi Alanazi[9], Fahad Mohammed Alenezi[10]

[1] Laboratory Specialist, Children's Hospital, Taif, Makkah Region, Saudi Arabia.
[2] Laboratory Specialist, Children's Hospital, Taif, Makkah Region, Saudi Arabia.
[3] Specialist-Laboratory, Aja Long-Term Care Hospital And Medical Rehabilitation Center, Hail, Hail Region, Saudi Arabia.
[4] Specialist-Laboratory, Ministry Of Health Branch, Al-Jouf Region, Saudi Arabia.
[5] Specialist-Laboratory, Aseer Regional Laboratory, Abha, Aseer Region, Saudi Arabia.
[6] Laboratory, Regional Laboratory, Madinah, Madinah Region, Saudi Arabia.
[7] Laboratory, King Abdulaziz Specialist Hospital, Taif, Makkah Region, Saudi Arabia.
[8] Technician-Laboratory, The Regional Laboratory, Madinah, Madinah Region, Saudi Arabia.
[9] Technician Laboratory, Extended Care Hospital, Arar, Northern Borders Region, Saudi Arabia.
[10] Laboratory, Maternity And Children Hospital, Arar, Northern Borders Region, Saudi Arabia.

Abstract:

Recent advancements in biomarker discovery for chronic kidney disease (CKD) have significantly enhanced the ability to detect the condition in its early stages, allowing for timely intervention and better patient outcomes. Traditional methods, such as serum creatinine levels and glomerular filtration rate (GFR), often fail to identify kidney damage until significant loss of function has occurred. However, the introduction of novel biomarkers—such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and urinary podocytes—has shown promise in providing a more sensitive and specific assessment of kidney health. High-throughput technologies, including proteomics and genomics, are being employed to identify potential biomarkers that are not only indicative of renal function but also reflect underlying pathophysiological processes, aiding in the stratification of CKD risk. Moreover, the integration of artificial intelligence and machine learning in biomarker research is revolutionizing early detection strategies. These technologies analyze vast datasets to identify patterns and correlations that may not be apparent through conventional statistical methods. CNK metrics, which assess cumulative nephron loss and renal reserve, are being developed as composite biomarkers that provide a more comprehensive picture of kidney health. As researchers continue to explore the molecular underpinnings of CKD, personalized medicine approaches are also emerging, allowing for tailored treatment plans based on individual biomarker profiles. These advancements hold the potential to transform CKD management, leading to better prevention strategies and improved quality of life for affected individuals.

Keywords: Chronic Kidney Disease (CKD), Biomarkers, Early Detection, Neutrophil gelatinase-associated lipocalin (NGAL), Kidney injury molecule-1 (KIM-1), Urinary podocytes, Proteomics, Genomics, Artificial Intelligence, Machine Learning, Cumulative Nephron Loss, Personalized Medicine.

Introduction:

Chronic kidney disease (CKD) is a progressive and often asymptomatic condition that poses a significant global health challenge. It affects millions of individuals worldwide and is associated with substantial morbidity, mortality, and healthcare costs. The global prevalence of CKD has reached alarming rates, with the World Health Organization estimating that one in ten adults is affected. Despite advancements in medical technology and treatment strategies, early detection remains a critical component in managing CKD effectively. The ability to identify patients at an early stage of kidney damage can lead to timely interventions that may slow disease progression, improve quality of life, and reduce the burden on healthcare systems. Accordingly, there has been a surge in research dedicated to the discovery and validation of

biomarkers that can facilitate the early detection of CKD [1].

Biomarkers are biological indicators that can signal the presence of a disease, inform on its progression, or predict treatment responses. In the context of CKD, the ideal biomarker should possess specificity and sensitivity, be easily measurable, and provide insights into the pathophysiological processes occurring in renal tissues. Traditional biomarkers for kidney function, such as serum creatinine and blood urea nitrogen (BUN), have significant limitations. Creatinine, while routinely used for estimating glomerular filtration rate (GFR), often fails to detect early kidney injury, as it may remain within normal ranges until substantial damage has occurred. Consequently, there is an urgent need for novel biomarkers that can detect CKD at earlier stages, allowing for more effective management and treatment strategies [2].

Recent advancements in biotechnology and omics sciences, particularly genomics, proteomics, and metabolomics, have propelled biomarker discovery to new heights. High-throughput technologies have facilitated the exploration of vast datasets, enabling researchers to identify potential biomolecules that correlate with the early phases of kidney disease. Specifically, the integration of these omics approaches has allowed for a comprehensive analysis of biological systems, providing a multi-faceted view of CKD. For instance, proteomic profiling can unveil differentially expressed proteins in the kidney or urinary matrix that signify early pathological changes associated with CKD [3].

Moreover, the advent of machine learning and artificial intelligence (AI) has made significant contributions to biomarker discovery. Machine learning algorithms can analyze complex datasets to identify patterns and predict outcomes based on biomarker profiles. This computational power enables researchers to sift through massive datasets rapidly, accelerating the identification of candidate biomarkers significantly. By honing in on specific indicators associated with CKD, these technologies can enhance the diagnostic precision and tailor interventions according to individual patient needs [4].

The search for effective biomarkers has also led to the exploration of soluble factors and urinary exosomes. Recent studies have uncovered the potential of molecules such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and urine biomarkers like albumin and microalbumin as early indicators of kidney stress and injury [5].

These biomarkers have shown promise in clinical settings and are currently being validated in various cohorts to assess their reliability and diagnostic utility.

It is also crucial to recognize the role of genetic factors in the pathogenesis of CKD. Genome-wide association studies (GWAS) have identified numerous genetic variants associated with the risk of CKD, suggesting a hereditary component to susceptibility. By integrating genetic information with biomarker profiles, healthcare providers may be able to identify individuals at risk for CKD even before clinical symptoms appear [6].

While substantial progress is being made in the identification and validation of CKD biomarkers, several challenges remain. Regulatory frameworks for biomarker approval, clinical utility validation, and economic considerations are essential factors influencing the adoption of new biomarkers in clinical practice. Moreover, the heterogeneity of CKD, driven by different etiologies and individual responses to injury, complicates the establishment of universally applicable biomarkers [7].

Despite these hurdles, ongoing research and innovation in biomarker discovery hold great potential for transforming CKD management. As the field evolves, there is a growing consensus that personalized medicine, leveraging the power of biomarkers to guide treatment, will play a pivotal role in optimizing patient care [8].

Traditional Diagnostic Methods: Limitations and Challenges:

Chronic Kidney Disease (CKD) is a progressive condition characterized by a gradual loss of kidney function over time, making it a significant global health issue. Affecting approximately 10% of the world's population, CKD leads to serious complications, including cardiovascular disease, kidney failure, and increased mortality rates. The increasing prevalence of CKD necessitates effective early diagnosis and management strategies. However, traditional diagnostic methods, which primarily include serum creatinine measurement,

estimated glomerular filtration rate (eGFR), urinalysis, and imaging techniques, face significant limitations and challenges in the timely and accurate diagnosis of this complex disease [9].

1. Serum Creatinine and eGFR Measurements

The cornerstone of CKD diagnosis has traditionally relied on serum creatinine levels and the calculation of eGFR. Serum creatinine, a waste product produced from muscle metabolism, is measured in blood tests and serves as a marker of kidney function. However, this method has its inherent limitations. Firstly, serum creatinine levels can be influenced by various factors, including age, sex, muscle mass, diet, and hydration status. For instance, in elderly patients or those with reduced muscle mass, serum creatinine levels may not accurately reflect kidney function, leading to underdiagnosis of CKD [10].

The eGFR, calculated using formulas such as the Modification of Diet in Renal Disease (MDRD) or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), further complicates the diagnostic landscape. While eGFR provides a standardized way to estimate kidney function, it is still susceptible to the same factors that impact serum creatinine levels. Additionally, these formulas often lack accuracy in special populations, including the elderly, individuals with obesity, and those with increased muscle mass. Consequently, patients may receive a delayed diagnosis due to these confounding variables [11].

2. Urinalysis: Insights and Limitations

Urinalysis is another essential component in the diagnostic process for CKD. This test assesses the composition of urine to detect abnormalities such as proteinuria, hematuria, and the presence of casts or crystals. Proteinuria, or the presence of excess protein in urine, is a critical marker of kidney damage and correlates with disease progression. However, traditional urinalysis methods can be limited by their inability to quantify levels of albumin, the primary protein of concern in kidney disease [12].

Moreover, urinalysis can be affected by factors such as hydration status and intermittent proteinuria, where protein levels fluctuate. This variability may lead to false-negative results, especially in patients with early-stage CKD. A single dipstick test may not reflect the chronic nature of proteinuria, potentially resulting in misdiagnosis or delayed intervention [12].

3. Imaging Techniques: The Diagnostic Dilemma

Imaging techniques, such as ultrasound and computed tomography (CT), play a role in CKD diagnosis, particularly when anatomical abnormalities are suspected. These modalities can help detect structural changes, including renal masses, hydronephrosis, or other urinary tract obstructions. However, their use is often limited by cost, availability, and the need for specialized equipment and expertise [13].

Additionally, imaging does not provide direct information about renal function or the extent of kidney damage, which is critical for CKD staging. For instance, an ultrasound may show normal kidney size and structure despite the presence of reduced kidney function, resulting in a false sense of security regarding the patient's renal health [13].

4. Need for Biomarkers: The Next Frontier

The limitations of traditional diagnostic methods for CKD have led to a growing demand for new biomarkers and technologies that can provide a more comprehensive and accurate assessment of kidney function. Research has identified potential biomarkers—such as cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1)—which may enhance early detection and risk stratification [14].

Cystatin C, in particular, has gained attention as an alternative to creatinine for estimating GFR because it is less affected by factors such as muscle mass, age, and sex. Additionally, biomarkers that detect tubular damage or inflammation may provide insights into the underlying pathophysiology of CKD and improve diagnostic accuracy.

Despite these advancements, challenges remain in integrating novel biomarkers into clinical practice. Issues surrounding cost, standardization, and validation of these tests must be addressed before widespread implementation can occur. Furthermore, a multifaceted approach that combines multiple diagnostic modalities—including traditional tests, imaging, and novel biomarkers—may yield the most effective strategy for CKD diagnosis and management [14].

Emerging Biomarkers: Innovations in Detection and Prognosis:

Chronic Kidney Disease (CKD) represents a significant global health burden, affecting millions of individuals worldwide. The disorder is characterized by a progressive decline in kidney function over time, leading to a myriad of complications including cardiovascular disease, anemia, and final-stage renal failure requiring dialysis or transplantation. Traditionally, the detection and diagnosis of CKD have relied on conventional biomarkers such as serum creatinine, blood urea nitrogen (BUN), and urine albumin levels. However, these markers fall short in early detection, sensitivity, and specificity, highlighting an urgent need for the identification and validation of novel biomarkers. Emerging biomarkers promise to enhance our understanding of CKD pathophysiology, facilitate earlier diagnosis, and pave the way for tailored therapeutic interventions [15].

CKD is defined as a reduction in kidney function that persists over a minimum of three months. The disease often progresses silently; many individuals remain asymptomatic until the later stages when irreversible damage has occurred. Common causes of CKD include diabetes mellitus, hypertension, and glomerulonephritis. As the prevalence of these conditions rises, early diagnosis and management of CKD become increasingly crucial [15].

Current methods for diagnosing CKD predominantly rely on serum creatinine levels, which reflect glomerular filtration rate (GFR). However, creatinine is influenced by factors such as age, muscle mass, and diet. Consequently, its elevation only occurs after a significant reduction in kidney function, often when the disease is already advanced. This limitation underscores the necessity for novel biomarkers that can provide earlier and more precise indicators of kidney damage [16].

The Role of Emerging Biomarkers

Emerging biomarkers can be broadly classified into several categories, including nephron-specific proteins, inflammatory mediators, and metabolic byproducts. These biomarkers have the potential to revolutionize CKD diagnosis across several dimensions: early detection, assessment of disease progression, and prediction of outcomes [17].

1. Nephron-Specific Proteins

One of the most promising avenues in CKD biomarker research involves nephron-specific proteins. For instance, an increase in urinary levels of **Neutrophil gelatinase-associated lipocalin (NGAL)** has been shown to occur in response to acute and chronic kidney injury. NGAL is released primarily by renal tubules and can be detected in urine shortly after injury occurs, making it a valuable early marker [18].

Another important nephron-specific biomarker is **Kidney Injury Molecule-1 (KIM-1)**, which is produced by proximal tubular cells. Elevated urinary KIM-1 levels correlate highly with tubule damage and have shown promise in predicting CKD progression. Similarly, **Interleukin-18 (IL-18)**, an inflammatory cytokine, has surfaced as another candidate that not only indicates injury but may also reflect the underlying inflammatory processes contributing to CKD pathology [19].

2. Inflammatory Markers

The role of inflammation in CKD has garnered considerable attention. Chronic inflammation is both a result and a contributor to renal disease progression. Biomarkers such as **C-reactive protein (CRP)** and **tumor necrosis factor-alpha (TNF-α)** have been investigated for their ability to correlate with CKD progression. Interestingly, recent studies have demonstrated that elevated levels of these inflammatory markers are associated with increased risk of cardiovascular events, which are prevalent in CKD patients [20].

Additionally, the discovery of novel inflammatory mediators like **steroid receptor RNA activator (SRA)** presents new opportunities for understanding the inflammatory milieu in CKD. These markers can provide insight into the systemic effects of renal impairment, and their monitoring could become essential in assessing disease status and therapeutic responses [21].

3. Metabolomics

Advancements in metabolomics—the comprehensive study of metabolites in biological samples—have opened new doors for CKD biomarker discovery. Metabolites such as **indoxyl sulfate** and **p-cresyl sulfate**, derived from protein metabolism, have been implicated in kidney damage and progression of renal disease. These uremic

toxins not only indicate declining kidney function but also contribute to additional comorbidities associated with CKD [22].

Another metabolomics-related biomarker is **TMAO (trimethylamine N-oxide)**, which has been linked to cardiovascular risk in CKD patients. Elevated TMAO levels have been associated with disease progression and may reflect the impact of gut microbiota on kidney health [23].

4. Genomic and Proteomic Approaches

The integration of genomics and proteomics into CKD biomarker discovery is another area of active research. High-throughput technologies allow for the identification of genetic variants associated with CKD susceptibility and progression. For instance, genes involved in fibrosis processes such as **FZD4** and **ADAMTS9** have been studied for their role in renal pathophysiology. Understanding the genetic predispositions to CKD can aid in risk assessment and in the development of personalized medicine approaches [24].

Challenges and Future Directions

Despite the promise of emerging biomarkers, several challenges remain. Validation of new markers is paramount; they must demonstrate not only efficacy in clinical settings but also cost-effectiveness and ease of use. Regulatory approval for clinical implementation is also critical, which often involves extensive clinical trials. Moreover, factors such as ethnic variability in response to biomarkers and comorbidity risks need consideration in diverse populations [25].

A future horizon includes harmonizing the use of these biomarkers within existing frameworks for CKD management. The integration of multiple biomarkers could provide a composite score that reflects both kidney function and underlying pathophysiology, enabling more accurate diagnosis and individualized treatment plans [26].

High-throughput Technologies in Biomarker Identification:

Chronic Kidney Disease (CKD) represents a significant public health challenge, affecting millions of individuals worldwide. Characterized by a gradual decline in kidney function, CKD can lead to serious complications, including end-stage renal disease and cardiovascular issues, ultimately increasing morbidity and mortality rates. The importance of early detection and intervention in CKD cannot be overstated, as timely therapeutic decisions can significantly alter the disease's progression and improve patient outcomes. In this context, the identification of reliable and innovative biomarkers for CKD plays a crucial role. High-throughput technologies have emerged as vital tools in biomarker research, allowing for the rapid and efficient analysis of biological samples [27].

Biomarkers are biological indicators that can provide valuable information about a disease's presence, severity, or prognosis. In CKD, biomarkers can serve several purposes, including the early detection of kidney dysfunction, the monitoring of disease progression, and the evaluation of therapeutic responses. Traditional markers, such as serum creatinine and estimated glomerular filtration rate (eGFR), have limitations due to their lack of sensitivity and specificity in the early stages of CKD. Consequently, there is a pressing need for novel biomarkers that can better reflect kidney damage and function [28].

The ideal biomarker for CKD should exhibit early detection capabilities, be readily measurable through non-invasive techniques, reflect the underlying pathophysiology, and predict clinical outcomes. High-throughput technologies offer promising avenues for the discovery of such biomarkers by enabling the simultaneous analysis of thousands of biological molecules, including proteins, metabolites, and nucleic acids [29].

High-Throughput Technologies

High-throughput technologies encompass a range of analytical methodologies capable of processing large volumes of biological samples quickly and efficiently. These technologies include omics approaches—such as genomics, proteomics, metabolomics, and transcriptomics—as well as advancements in imaging and bioinformatics. Each of these methodologies contributes uniquely to biomarker discovery and validation [30].

1. **Genomics**: The field of genomics focuses on the comprehensive analysis of an organism's genetic material. High-throughput sequencing techniques, such as next-generation sequencing (NGS), allow researchers to identify genetic variants associated with CKD susceptibility.

Genome-wide association studies (GWAS) leverage these technologies to pinpoint associations between specific genetic markers and CKD outcomes. For instance, variants in the APOL1 gene have been linked to increased risk for CKD in certain populations, highlighting the role of genetic predisposition in the disease's pathogenesis [31].

2. **Proteomics**: Proteomics is the study of the entire set of proteins expressed in a biological sample at a given time. Utilizing techniques like mass spectrometry, researchers can identify differentially expressed proteins that may serve as biomarkers for CKD. For example, proteins such as nephrin and urinary podocalyxin have shown promise as biomarkers for podocyte injury in early CKD. The integration of proteomic data with clinical parameters can also enhance the predictive power for disease progression [32].
3. **Metabolomics**: Metabolomics analyzes small metabolites present in biological fluids, revealing information about metabolic changes associated with diseases. Techniques such as liquid chromatography-mass spectrometry (LC-MS) allow for the identification of metabolites linked to CKD. For instance, abnormalities in amino acid metabolism and lipid profiles have been associated with CKD progression. Metabolomic profiling can lead to the discovery of novel biomarkers that may predict disease risk or severity.
4. **Transcriptomics**: Transcriptomics involves analyzing RNA transcripts to understand gene expression patterns. High-throughput techniques, such as RNA sequencing, allow researchers to identify differences in gene expression associated with CKD. Biomarkers identified through transcriptomics may aid in understanding the molecular mechanisms driving CKD and help in identifying therapeutic targets [33].

Advantages of High-Throughput Technologies

The advantages of high-throughput technologies in biomarker discovery are manifold. Firstly, they enable the rapid screening of a vast number of candidates, significantly reducing the time required to identify potential biomarkers. Secondly, these technologies can elucidate complex biological pathways and interactions that underlie CKD, offering insight into the disease's multifactorial nature. Thirdly, high-throughput platforms usually require smaller sample volumes, which is particularly beneficial in clinical settings where sample availability may be limited. Furthermore, the integration of high-throughput data with advanced bioinformatics allows for a more comprehensive analysis and validation of the identified biomarkers [34].

Despite their potential, high-throughput technologies face several limitations. The detection of biomarkers is often influenced by confounding factors, including age, sex, comorbidities, and medication use, which can complicate the interpretation of results. Additionally, reproducibility and validation of discovered biomarkers remain challenges, as many candidate biomarkers fail to perform reliably in larger, diverse populations following initial discovery. Moreover, high-throughput approaches often generate vast amounts of data that require sophisticated bioinformatics tools for analysis, necessitating interdisciplinary collaboration between biologists and computational scientists [35].

As the field of high-throughput biomarker discovery continues to evolve, several key implications for CKD management and research can be anticipated. The identification of novel biomarkers could enhance screening practices, enabling earlier diagnosis and intervention for at-risk populations. Integrating biomarker data with clinical assessments could lead to more personalized approaches to CKD management, allowing for tailored therapies that align with individual patient profiles [36].

Furthermore, advancements in high-throughput technologies are likely to spur the development of new therapeutic strategies targeting specific pathways implicated in CKD. By elucidating the biological underpinnings of CKD through high-throughput analysis, researchers can identify molecular targets for drug development, potentially

leading to innovative treatments that could halt or even reverse disease progression [37].

Role of Artificial Intelligence in Advancing Biomarker Research:

Chronic kidney disease (CKD) has emerged as a significant global health concern, affecting millions of individuals worldwide. This complex and multifactorial condition is characterized by a gradual loss of kidney function over time, leading to severe complications such as cardiovascular disease, renal failure, and increased mortality. As the prevalence of CKD rises, the medical community is urgently seeking innovative methods to enhance the diagnosis, prognosis, and treatment of this condition. One of the most promising developments in this regard is the application of artificial intelligence (AI) techniques in biomarker research. By allowing for the analysis of vast datasets, the identification of novel biomarkers, and the acceleration of clinical decision-making, AI is playing an increasingly indispensable role in advancing our understanding and management of CKD [38].

Biomarkers can be defined as measurable indicators of a biological process, condition, or disease. In the context of CKD, biomarkers offer valuable information regarding the health of the kidneys and the progression of the disease. They can serve various functions: early detection of CKD, assessment of disease severity, prediction of outcomes, and monitoring the efficacy of therapeutic interventions. Traditionally, biomarkers such as serum creatinine and urinary albumin excretion have been utilized in clinical practice. However, these biomarkers exhibit limitations, including delayed response to kidney damage and insufficient sensitivity in early disease stages [39].

To address these shortcomings, research efforts have been directed towards the identification of novel biomarkers that provide more timely and accurate indications of kidney health. These investigations often involve complex biochemical analyses and high-dimensional omics data generated from genomics, proteomics, and metabolomics studies. The challenge lies in interpreting these extensive datasets to uncover meaningful insights. Here, AI demonstrates its value as a transformative tool in the realm of biomarker research in CKD [40].

AI encompasses various computational techniques designed to emulate human cognitive functions, including machine learning (ML) and deep learning (DL). These algorithms can analyze and interpret large volumes of data with extraordinary speed and precision. In biomarker research, AI can process data from electronic health records, imaging studies, and omics technologies, thus enabling the detection of patterns and correlations that would be impossible for humans to discern [41].

One prominent application of AI in CKD biomarker research is the development of predictive models for disease progression. By integrating diverse datasets—such as demographic information, clinical presentations, laboratory results, and genetic data—researchers can create sophisticated algorithms that identify individuals at high risk of developing CKD or progressing to end-stage renal disease. For instance, machine learning models have been employed to predict the onset of diabetic nephropathy, a common complication of diabetes that significantly contributes to CKD. Through these predictive analyses, interventions can be tailored to at-risk patients, potentially altering disease trajectories [42].

The exploration of novel biomarkers for CKD is another area where AI is making significant contributions. Recent advancements in technologies, such as mass spectrometry and next-generation sequencing, have enabled the generation of extensive biomolecular profiles. However, deciphering the biological significance of these profiles requires advanced analytical methods [43].

AI techniques, particularly unsupervised learning algorithms, can sift through high-dimensional data to identify novel biomolecules associated with CKD. For example, researchers have successfully utilized AI to uncover potential protein biomarkers linked to renal fibrosis, which is a hallmark of CKD progression. By identifying these new biomarkers, healthcare professionals may gain insights into the underlying mechanisms of CKD, paving the way for targeted therapies that can halt or even reverse kidney damage [44].

Moreover, AI-assisted image analysis is revolutionizing the process of detecting kidney pathologies. Machine learning models can be trained to analyze histopathological images and identify subtle changes indicative of CKD long before they

are apparent to the naked eye. This capability lends itself to enhancing the diagnostic accuracy of kidney biopsies, ensuring timely intervention and improved patient outcomes [45].

One of the most compelling applications of AI lies in enhancing clinical decision-making in the management of CKD. AI algorithms can be integrated into clinical settings to provide decision support for healthcare providers. Such systems can analyze patient data in real time, delivering insights and recommendations that align with the latest evidence-based practices [46].

For instance, AI-driven tools can aid in the interpretation of biomarker panels and assist clinicians in selecting the most appropriate treatment options based on individualized patient profiles. Additionally, these smart systems can help identify potential drug interactions and contraindications, thereby optimizing therapeutic regimens. Given the complex and personalized nature of CKD management, the integration of AI into routine clinical practice holds the promise of transforming patient care [47].

While the prospects of AI in advancing biomarker research in CKD appear bright, several challenges must be addressed. Data privacy and security concerns surrounding the use of large health datasets pose a significant barrier to AI implementation. The development of robust data governance frameworks is essential to ensure the ethical use of patient data. Additionally, the risk of algorithmic bias underscores the need for diverse and representative datasets in training AI models [47].

Furthermore, the clinical validation of AI-generated biomarkers remains a critical hurdle. Findings derived from AI analyses must undergo rigorous validation in diverse populations and clinical settings to establish their utility in improving patient outcomes. Collaborative efforts between researchers, clinicians, and regulatory agencies will be essential in overcoming these challenges [48].

Integrative Approaches: Combining Biomarkers for Enhanced Accuracy:

Chronic kidney disease (CKD) is a significant global health challenge, affecting millions of people and leading to substantial morbidity and mortality. As a progressive condition characterized by a gradual decline in kidney function, CKD often remains undetected until advanced stages when interventions become less effective. Thus, accurate and timely diagnosis is pivotal for effective management and improved patient outcomes. Recent advancements in the understanding of biomarkers and their potential applications in clinical settings have paved the way for an integrative approach to the diagnosis and management of CKD [48].

Biomarkers are biological indicators that can be measured objectively and indicate a pathological process, physiological response, or pharmacological response to a therapeutic intervention. In the context of CKD, biomarkers are instrumental in assessing kidney function, identifying kidney damage, and predicting disease progression. Commonly used biomarkers include serum creatinine, blood urea nitrogen (BUN), and urine albumin. Typically, serum creatinine levels serve as the cornerstone for estimating glomerular filtration rate (eGFR), a critical parameter for determining renal function. However, while conventional markers have served as foundational tools in nephrology, they possess several limitations, particularly regarding sensitivity and specificity in detecting early kidney injury [49].

Single biomarkers, such as serum creatinine, can provide valuable insights into kidney function, but they often fail to detect early kidney damage or reflect the complex interplay of factors influencing kidney health. Serum creatinine levels can remain within the normal range for a significant period during the initial stages of CKD due to adaptive mechanisms, thereby delaying diagnosis until irreparable damage has occurred. Furthermore, factors such as age, muscle mass, diet, and hydration status can influence creatinine levels, leading to potential misinterpretations [49].

Additionally, while albuminuria is an important indicator of kidney pathology, it is not exclusively linked to CKD and can be influenced by other conditions, such as diabetes or hypertension. As a result, relying on individual biomarkers for diagnosing CKD can result in suboptimal clinical decision-making, leading to missed opportunities for early intervention [49].

The limitations of single biomarkers underscore the necessity for integrative approaches that combine multiple biomarkers to enhance diagnostic precision and predictive power. Integrating various biomarkers can lead to a more comprehensive

understanding of kidney health. This integrated perspective considers the multifactorial nature of CKD, allowing healthcare providers to evaluate both the severity of damage and the underlying mechanisms contributing to disease progression [50].

In recent years, there has been a burgeoning interest in identifying novel biomarkers that may facilitate better detection of kidney injury. Biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and cystatin C have emerged as promising candidates. NGAL is released during acute kidney injury and can be identified in urine or serum; KIM-1 is a tubular injury marker that reflects kidney damage; while cystatin C provides an alternative measure of renal function unconfounded by muscle mass [50].

The combination of biomarkers can significantly improve the accuracy of CKD diagnosis, guiding treatment choices. By utilizing a multimodal biomarker approach, clinicians can achieve a more precise renal risk stratification, better predicting disease progression and outcomes. For instance, studies have demonstrated that combining creatinine levels with biomarkers like NGAL can enhance the early detection of acute kidney injury, leading to more timely interventions [51].

Moreover, an integrative approach allows for personalized medicine, where treatment regimens can be tailored based on the specific biomarker profile of an individual patient. This framework considers the patient's unique genetic, environmental, and lifestyle factors. For example, patients exhibiting elevated levels of KIM-1 may benefit from more aggressive blood pressure control or dietary modifications to avert further decline in renal function [51].

While the scientific rationale for combining biomarkers is compelling, several challenges exist in implementing these integrative approaches in clinical practice. Validation of new biomarkers must be rigorous, involving large-scale clinical trials to establish their utility, reliability, and cost-effectiveness. Furthermore, the integration of biomarker testing into routine clinical practice necessitates an overarching framework that encompasses education for healthcare providers, standardization of testing protocols, and established guidelines for interpretation [52].

Additionally, the role of technology in biomarker integration cannot be overlooked. Artificial intelligence (AI) and machine learning algorithms can analyze complex biomarker profiles and predict disease trajectories, enabling proactive management strategies. By synthesizing data from various biomarkers, electronic health records, and clinical parameters, these technologies can enhance the decision-making processes for healthcare providers [52].

Clinical Implications of Early Biomarker Detection in CKD Management:

Chronic Kidney Disease (CKD) is a growing global health concern, characterized by a gradual loss of kidney function over time. Affecting approximately 10-15% of the global population, CKD presents significant challenges, including increased morbidity, decreased quality of life, and substantial healthcare costs. The implications of CKD extend beyond the kidneys themselves, impacting various organ systems and leading to complications such as cardiovascular disease, which is prevalent among those with renal impairment. Given the intricate nature of managing CKD, researchers and clinicians are continuously seeking effective strategies to enhance early diagnosis and treatment. A promising avenue is the detection of biomarkers, particularly in the early stages of the disease [52].

Biomarkers are biological indicators that can be measured and evaluated to assess health conditions, predict disease progression, or gauge the effectiveness of therapeutic interventions. In the context of CKD, various biomarkers have been identified, including serum creatinine, cystatin C, urine albumin, and novel biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1). Each of these biomarkers provides valuable information regarding renal function, damage, and the pathophysiological processes underpinning kidney disease [53].

The traditional approach to diagnosing CKD largely relies on serum creatinine levels and estimated glomerular filtration rate (eGFR). However, these metrics often fail to detect renal impairment until a significant loss of kidney function has occurred. This limitation underscores the necessity of identifying biomarkers that can signal renal dysfunction earlier, allowing for timely

interventions that may slow the disease's progression [53].

The Benefits of Early Biomarker Detection

1. **Timely Diagnosis and Intervention**: One of the most significant clinical implications of early biomarker detection is the potential for timely diagnosis. Early identification of CKD can facilitate prompt intervention, which is crucial for slowing progression and reducing the risk of advancements to end-stage renal disease (ESRD). For instance, the use of urinary biomarkers such as NGAL and KIM-1 can indicate acute kidney injury before conventional methods can, allowing for the implementation of preventative measures that might preserve renal function [54].
2. **Personalized Treatment Strategies**: The advent of precision medicine, which tailors treatment based on individual patient characteristics, highlights another important benefit of early biomarker detection. By integrating biomarkers into routine testing, clinicians can determine the underlying cause of CKD in each patient, which can guide specific therapeutic strategies. For instance, identifying patients with diabetic kidney disease versus hypertensive kidneys can lead to targeted approaches that address the underlying metabolic syndrome more effectively, hence preserving kidney function over time [54].
3. **Risk Stratification**: Biomarkers can aid in risk stratification, allowing healthcare providers to categorize patients based on their likelihood of experiencing complications associated with CKD. This stratification enables a more proactive approach to management, where clinicians can prioritize resources and tailor surveillance protocols according to individual risk profiles. Such strategies can prevent the unnecessary allocation of healthcare resources to low-risk patients while ensuring that high-risk patients receive the required attention and intervention [55].
4. **Monitoring Disease Progression**: Continuous monitoring of biomarker levels can provide insights regarding disease progression in CKD patients. For instance, serial measurements of albuminuria have been associated with renal prognosis, with significant prognostic implications based on the trajectory of urine albumin levels over time. This monitoring allows for dynamic adjustments in therapy and facilitates discussions around prognosis between clinicians and patients [55].
5. **Enhanced Patient Education and Engagement**: Early biomarker detection can also promote patient engagement in their own care. When patients are educated about their biomarkers and their significance, they are empowered to take an active role in managing their health. Understanding how changes in biomarkers correlate with lifestyle factors, such as diet and medication adherence, can motivate patients to adopt healthier habits, which can ultimately lead to improved outcomes [56].

Challenges and Considerations

Despite the clear benefits associated with early biomarker detection, several challenges remain. First, further validation of biomarkers in diverse populations is necessary to ensure reliability and applicability in various clinical settings. Additionally, the integration of novel biomarkers into routine clinical practice requires validation studies to calculate the cost-effectiveness of implementing these biomarkers compared to traditional methods. The healthcare system must also overcome barriers related to access to advanced diagnostic technologies, especially in low-resource settings where CKD is often underdiagnosed and undertreated.

Furthermore, ethical considerations surrounding the use of biomarkers raise important questions regarding patient consent, data privacy, and the psychosocial impact of early diagnosis. Ensuring that patients are adequately informed about the implications of early biomarker tests—and potentially a diagnosis of CKD—will be paramount in maintaining patient trust and compliance [57].

Future Directions in Biomarker Research: Towards Personalized Medicine:

Chronic Kidney Disease (CKD) represents a significant global health challenge, affecting approximately 10% of the population worldwide. As a progressive disorder, CKD often culminates in end-stage renal disease, necessitating costly interventions such as dialysis or kidney transplantation. The burden of CKD is further exacerbated by the comorbid conditions it frequently accompanies, including hypertension and diabetes. As the healthcare landscape continues to evolve, research focused on biomarkers is gaining traction, promising to revolutionize the management of CKD [57].

Biomarkers are measurable indicators of biological processes, diseases, or responses to therapeutic intervention. In the context of CKD, biomarkers serve several critical functions: aiding in the diagnosis, predicting disease progression, guiding treatment decisions, and assessing treatment efficacy. Historically, the diagnosis of CKD has primarily relied on serum creatinine levels and glomerular filtration rate (GFR) estimates. However, these conventional markers often fail to accurately reflect kidney function in certain populations, particularly in early-stage CKD, where compensatory mechanisms may mask underlying damages. Therefore, the need for innovative biomarkers that can more precisely stratify CKD patients is paramount [58].

The future of biomarker discovery is likely to benefit from advancements in technology and methodologies. Techniques such as genomic sequencing, proteomics, metabolomics, and transcriptomics are revealing a wealth of information about diseases at a molecular level. For CKD, integrated -omics approaches may help uncover novel biomarkers associated with the disease at various stages, enabling early detection and better prediction of disease trajectories [58].

For example, the use of urinary biomarkers is emerging as a promising avenue due to the non-invasive nature of urine collection. Research has identified potential urinary biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1), which have shown promise in indicating acute kidney injury and predicting CKD progression. Future studies will need to validate these findings in larger, diverse populations to establish their utility in routine clinical practice [59].

Genetic research is poised to make significant contributions to the field of biomarker research in CKD. Genome-wide association studies (GWAS) have already identified genetic variants linked to kidney diseases, offering insights into the underlying mechanisms of CKD. By understanding the genetic predispositions to CKD, clinicians can potentially tailor preventive and therapeutic strategies based on a patient's genetic profile [59].

Pharmacogenomics, the study of how genes affect a person's response to drugs, is another exciting frontier. Given that CKD patients often require medications that may not yield the same therapeutic effects across individuals, pharmacogenomic information could guide dosage decisions and drug selections, minimizing adverse effects and optimizing efficacy [60].

As CKD is a complex and multifactorial disease, the future of biomarker research will increasingly focus on integrative and multi-omics approaches. By combining data from genomics, proteomics, metabolomics, and environmental factors, researchers can create a comprehensive profile of each patient. This holistic approach can reveal interactions among various biomolecular pathways, potentially leading to the identification of panels of biomarkers that offer more predictive power than single markers alone [60].

Machine learning and artificial intelligence (AI) are becoming integral to integrating this diverse data. These technologies can process vast datasets to identify patterns and correlations that may not be immediately evident to human researchers. As these tools evolve, we can expect more refined biomarkers for CKD that inform personalized treatment strategies [61].

The transition towards personalized medicine in CKD necessitates a paradigm shift in clinical practice. With improved biomarkers, clinicians could move away from a one-size-fits-all approach toward personalized treatment regimens tailored to the unique characteristics of each patient, including their biomarker profiles, genetic predispositions, and comorbid conditions. This customization will enable earlier interventions and more effective

management, potentially mitigating CKD progression and improving patient outcomes [61].

Furthermore, understanding an individual's biomarker profile can help in stratifying patients into risk categories. High-risk individuals could undergo closer monitoring and proactive management, while lower-risk patients might benefit from preventative strategies, such as lifestyle modifications or targeted pharmacotherapy [62].

Despite the promising future of biomarker research in CKD, several barriers remain. Regulatory hurdles can impede the translation of new biomarkers from research settings to clinical applications. The establishment of standard protocols for biomarker validation is crucial to ensure consistency and reliability in measurements [62].

Moreover, there is a pressing need for interdisciplinary collaboration among kidney specialists, geneticists, data scientists, and regulatory bodies. Collaborative efforts can facilitate the sharing of data and insights, accelerating the pace of biomarker discovery and implementation [63].

Patient engagement is another vital component of advancing personalized medicine. Patients must be educated about the benefits of biomarker testing and integrated treatment pathways. Their willingness to participate in studies and clinical trials can significantly influence the progress of biomarker research [63].

Conclusion:

The advancements in biomarker discovery for the early detection of chronic kidney disease (CKD) represent a significant leap forward in nephrology, with the potential to transform patient management and outcomes. Traditional diagnostic methods often fall short in identifying renal impairment until substantial damage has occurred, underscoring the necessity for more sensitive and specific biomarkers. The identification of novel biomarkers, such as NGAL and KIM-1, combined with high-throughput technologies and artificial intelligence, has opened new avenues for early diagnosis and risk stratification.

Integrating these biomarkers into clinical practice can facilitate timely interventions, reducing the progression of CKD and its associated complications. Furthermore, the movement towards personalized medicine, utilizing individual patient biomarker profiles, promises to enhance therapeutic efficacy and improve quality of life for patients at risk of or suffering from CKD. Continued research and clinical validation of these biomarkers will be critical in realizing their full potential, ultimately paving the way for a proactive approach to kidney health that benefits both patients and healthcare systems.

References:

1. Gansevoort R.T., Correa-Rotter R., Hemmelgarn B.R., Jafar T.H., Heerspink H.J.L., Mann J.F., Matsushita K., Wen C.P. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–352. doi: 10.1016/S0140-6736(13)60595-4.
2. Zhang W.R., Parikh C.R. Biomarkers of Acute and Chronic Kidney Disease. Annu. Rev. Physiol. 2019;81:309–333. doi: 10.1146/annurev-physiol-020518-114605.
3. Uwaezuoke S.N., Ayuk A.C., Muoneke V.U., Mbanefo N.R. Chronic kidney disease in children: Using novel biomarkers as predictors of disease. Saudi J. Kidney Dis. Transpl. 2018;29:775–784. doi: 10.4103/1319-2442.239657.
4. Hill N.R., Fatoba S.T., Oke J.L., Hirst J.A., O'Callaghan C.A., Lasserson D.S., Hobbs F.D.R. Global Prevalence of Chronic Kidney Disease—A Systematic Review and Meta-Analysis. PLoS ONE. 2016;11:e0158765. doi: 10.1371/journal.pone.0158765.
5. Krstic D., Tomic N., Radosavljevic B., Avramovic N., Dragutinovic V., Radojevic Skodric S., Colovic M. Biochemical Markers of Renal Function. Curr. Med. Chem. 2016;23:2018–2040. doi: 10.2174/0929867323666160115130241.
6. Webster A.C., Nagler E.V., Morton R.L., Masson P. Chronic Kidney Disease. Lancet. 2017;389:1238–1252. doi: 10.1016/S0140-6736(16)32064-5.
7. Said S., Hernandez G.T. The link between chronic kidney disease and cardiovascular

disease. J. Nephropathol. 2014;3:99–104. doi: 10.12860/jnp.2014.19.

8. Neuner-Jehle M., Denizot J.P., Borbély A.A., Mallet J. Characterization and sleep deprivation-induced expression modulation of dendrin, a novel dendritic protein in rat brain neurons. J. Neurosci. Res. 1996;46:138–151. doi: 10.1002/(SICI)1097-4547(19961015)46:2<138::AID-JNR2>3.0.CO;2-I.
9. Steubl D., Block M., Herbst V., Nockher W.A., Schlumberger W., Satanovskij R., Angermann S., Hasenau A.L., Stecher L., Heemann U., et al. Plasma Uromodulin Correlates with Kidney Function and Identifies Early Stages in Chronic Kidney Disease Patients. Medicine. 2016;95:e3011. doi: 10.1097/MD.0000000000003011.
10. D'Marco L., Bellasi A., Raggi P. Cardiovascular biomarkers in chronic kidney disease: State of current research and clinical applicability. Dis. Markers. 2015;2015:586569. doi: 10.1155/2015/586569.
11. Watson D., Yang J.Y.C., Sarwal R.D., Sigdel T.K., Liberto J.M., Damm I., Louie V., Sigdel S., Livingstone D., Soh K., et al. A Novel Multi-Biomarker Assay for Non-Invasive Quantitative Monitoring of Kidney Injury. J. Clin. Med. 2019;8:499. doi: 10.3390/jcm8040499.
12. Inker L.A., Tighiouart H., Coresh J., Foster M.C., Anderson A.H., Beck G.J., Contreras G., Greene T., Karger A.B., Kusek J.W. GFR Estimation Using β-Trace Protein and β2-Microglobulin in CKD. Am. J. Kidney Dis. 2016;67:40–48. doi: 10.1053/j.ajkd.2015.07.025.
13. Pasala S., Carmody J.B. How to use serum creatinine, cystatin C and GFR. Arch. Dis. Child. Educ. Pract. Ed. 2017;102:37–43. doi: 10.1136/archdischild-2016-311062.
14. Fassett R.G., Venuthurupalli S.K., Gobe G.C., Coombes J.S., Cooper M.A., Hoy W.E. Biomarkers in chronic kidney disease: A review. Kidney Int. 2011;80:806–821. doi: 10.1038/ki.2011.198.
15. Zhang W.R., Parikh C.R. Biomarkers of Acute and Chronic Kidney Disease. Annu. Rev. Physiol. 2019;81:309–333. doi: 10.1146/annurev-physiol-020518-114605.
16. Donadio C. Serum and urinary markers of early impairment of GFR in chronic kidney disease patients: Diagnostic accuracy of urinary β-trace protein. Am. J. Physiol. Renal Physiol. 2010;299:f1407–f1423. doi: 10.1152/ajprenal.00507.2009.
17. Yamaguchi J., Tanaka T., Nangaku M. Recent advances in understanding of chronic kidney disease. F1000Res. 2015;4 doi: 10.12688/f1000research.6970.1.
18. Motawi T.K., Shehata N.I., ElNokeety M.M., El-Emady Y.F. Potential serum biomarkers for early detection of diabetic nephropathy. Diabetes Res. Clin. Pract. 2018;136:150–158. doi: 10.1016/j.diabres.2017.12.007.
19. Eckardt K.U., Coresh J., Devuyst O., Johnson R.J., Kottgen A., Levey A.S., Levin A. Evolving importance of kidney disease: From subspecialty to global health burden. Lancet. 2013;382:158–169. doi: 10.1016/S0140-6736(13)60439-0.
20. Foster M.C., Levey A.S., Inker L.A., Shafi T., Fan L., Gudnason V., Katz R., Mitchell G.F., Okparavero A., Palsson R., et al. Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in the Elderly: AGES-Kidney and MESA-Kidney. Am. J. Kidney Dis. 2017;70:406–414. doi: 10.1053/j.ajkd.2017.03.021.
21. Donadio C., Bozzoli L. Urinary beta-trace protein: A unique biomarker to screen early glomerular filtration rate impairment. Medicine. 2016;95:e5553. doi: 10.1097/MD.0000000000005553.
22. Schlondorff D.O. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int. 2008;74:860–866. doi: 10.1038/ki.2008.351.

23. Inker L.A., Tighiouart H., Coresh J., Foster M.C., Anderson A.H., Beck G.J., Contreras G., Greene T., Karger A.B., Kusek J.W., et al. GFR Estimation Using beta-Trace Protein and beta2-Microglobulin in CKD. Am. J. Kidney Dis. 2016;67:40–48. doi: 10.1053/j.ajkd.2015.07.025.

24. Dajak M., Ignjatovic S., Stojimirovic B., Gajic S., Majkic-Singh N. Evaluation of renal damage by urinary beta-trace protein in patients with chronic kidney disease. Clin. Lab. 2011;57:29–36.

25. George J.A., Gounden V. Novel glomerular filtration markers. Adv. Clin. Chem. 2019;88:91–119. doi: 10.1016/bs.acc.2018.10.005.

26. Levin A., Stevens P.E., Bilous R.W., Coresh J., De Francisco A.L.M., De Jong P.E., Griffith K.E., Hemmelgarn B.R., Iseki K., Lamb E.J., et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2012;3:1–150. doi: 10.1111/j.1600-6143.2009.02834.x.

27. Foundation N.K. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002;39:S1–S266.

28. Spanaus K.S., Kollerits B., Ritz E., Hersberger M., Kronenberg F., von Eckardstein A. Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin. Chem. 2010;56:740–749. doi: 10.1373/clinchem.2009.138826.

29. Filler G., Kusserow C., Lopes L., Kobrzyński M. Beta-trace protein as a marker of GFR--history, indications, and future research. Clin. Biochem. 2014;47:1188–1194. doi: 10.1016/j.clinbiochem.2014.04.027.

30. Ewadh M. Beta trace protein level as a better diagnostic marker of renal impairment in patients with chronic kidney disease, diabetes mellitus, and renal transplants. J. Pharm. Sci. Res. 2018;10:1615–1618.

31. Levey A.S., Coresh J. Chronic kidney disease. Lancet. 2012;379:165–180. doi: 10.1016/S0140-6736(11)60178-5.

32. Chen N., Shi H., Zhang L., Zuo L., Xie J., Xie D., Karger A.B., Miao S., Ren H., Zhang W., et al. GFR Estimation Using a Panel of Filtration Markers in Shanghai and Beijing. Kidney Med. 2020;2:172–180. doi: 10.1016/j.xkme.2019.11.004.

33. Kandasamy Y., Smith R., Lumbers E.R., Rudd D. Nephrin—A biomarker of early glomerular injury. Biomark. Res. 2014;2:21. doi: 10.1186/2050-7771-2-21.

34. Nakamura T., Ushiyama C., Suzuki S., Hara M., Shimada N., Ebihara I., Koide H. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol. Dial. Transplant. 2000;15:1379–1383. doi: 10.1093/ndt/15.9.1379.

35. Akankwasa G., Jianhua L., Guixue C., Changjuan A., Xiaosong Q. Urine markers of podocyte dysfunction: A review of podocalyxin and nephrin in selected glomerular diseases. Biomark. Med. 2018;12:927–935. doi: 10.2217/bmm-2018-0152.

36. Huber T.B., Simons M., Hartleben B., Sernetz L., Schmidts M., Gundlach E., Saleem M.A., Walz G., Benzing T. Molecular basis of the functional podocin–nephrin complex: Mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains. Hum. Mol. Genet. 2003;12:3397–3405. doi: 10.1093/hmg/ddg360.

37. ElShaarawy A., Abdelmoneim Behairy M., Bawady S.A., Abdelsattar H.A., Shadad E. Urinary podocin level as a predictor of diabetic kidney disease. J. Nephropathol. 2019;8:e26. doi: 10.15171/jnp.2019.26.

38. Zeng J., Zhang X., Yu R., Tang Y., Luo W.J., Chen C., Wu Y.J. Research on the combined detection of urine UmAlb and urinary nephrin, podocalyxin in podocyte

of MKR mice with diabetic nephropathy. Sichuan Da Xue Xue Bao Yi Xue Ban. 2015;46:722–725.

39. Surya M., Rajappa M., Vadivelan M. Utility of Urinary Nephrin in Patients with and Without Diabetic Nephropathy and Its Correlation with Albuminuria. Cureus. 2021;13:e20102. doi: 10.7759/cureus.20102.

40. Mizdrak M., Vukojević K., Filipović N., Čapkun V., Benzon B., Durdov M.G. Expression of DENDRIN in several glomerular diseases and correlation to pathological parameters and renal failure—Preliminary study. Diagn. Pathol. 2018;13:90. doi: 10.1186/s13000-018-0767-z.

41. Kostovska I., Tosheska-Trajkovska K., Topuzovska S., Cekovska S., Spasovski G., Kostovski O., Labudovic D. Urinary nephrin is earlier, more sensitive and specific marker of diabetic nephropathy than microalbuminuria. J. Med. Biochem. 2020;39:83–90. doi: 10.2478/jomb-2019-0026.

42. Rahman H.S.A., Hadhoud K., Bakr H.G., Youssef M.K. Assessment of Urinary Podocin Level as an Early Indicator in Diabetic Nephropathy. Zagazig Univ. Med. J. 2019;25:682–688. doi: 10.21608/zumj.2019.10380.10960.

43. Jim B., Ghanta M., Qipo A., Fan Y., Chuang P.Y., Cohen H.W., Abadi M., Thomas D.B., He J.C. Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: A cross sectional study. PLoS ONE. 2012;7:e36041. doi: 10.1371/journal.pone.0036041.

44. Camici M. Urinary biomarkers of podocyte injury. Biomark. Med. 2008;2:613–616. doi: 10.2217/17520363.2.6.613.

45. Liu Z., Zhou H., Chen X., Chen H., Wang Y., Wang T., Cai L., Hong Y., Ke H., Zheng J. Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease. Int. Urol. Nephrol. 2019;51:503–507. doi: 10.1007/s11255-019-02079-4.

46. Zheng S., Chen Y., Zheng Y., Zhou Z., Li Z. Correlation of serum levels of fibroblast growth factor 23 and Klotho protein levels with bone mineral density in maintenance hemodialysis patients. Eur. J. Med. Res. 2018;23:18. doi: 10.1186/s40001-018-0315-z.

47. Memmos E., Sarafidis P., Pateinakis P., Tsiantoulas A., Faitatzidou D., Giamalis P., Vasilikos V., Papagianni A. Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis. BMC Nephrol. 2019;20:217. doi: 10.1186/s12882-019-1391-1.

48. Hu M.-C., Kuro-o M., Moe O.W. Klotho and kidney disease. J. Nephrol. 2010;23(Suppl. 16):S136–S144.

49. Pottel H., Schaeffner E., Ebert N. Evaluating the diagnostic value of rescaled beta-trace protein in combination with serum creatinine and serum cystatin C in older adults. Clin. Chim. Acta. 2018;480:206–213. doi: 10.1016/j.cca.2018.02.026.

50. He T., Xiong J., Huang Y., Zheng C., Liu Y., Bi X., Liu C., Han W., Yang K., Xiao T., et al. Klotho restrain RIG-1/NF-κB signaling activation and monocyte inflammatory factor release under uremic condition. Life Sci. 2019;231:116570. doi: 10.1016/j.lfs.2019.116570.

51. Inker L.A., Coresh J., Sang Y., Hsu C.Y., Foster M.C., Eckfeldt J.H., Karger A.B., Nelson R.G., Liu X., Sarnak M., et al. Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis. Clin. J. Am. Soc. Nephrol. 2017;12:69–78. doi: 10.2215/CJN.03660316.

52. Zou D., Wu W., He Y., Ma S., Gao J. The role of klotho in chronic kidney disease. BMC Nephrol. 2018;19:285. doi: 10.1186/s12882-018-1094-z.

53. Wang Q., Su W., Shen Z., Wang R. Correlation between Soluble α-Klotho and Renal Function in Patients with Chronic Kidney Disease: A Review and Meta-Analysis. Biomed. Res. Int.

2018;2018:9481475. doi: 10.1155/2018/9481475.

54. Hong Y.A., Lim J.H., Kim M.Y., Kim Y., Yang K.S., Chung B.H., Chung S., Choi B.S., Yang C.W., Kim Y.S., et al. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease. Clin. Exp. Nephrol. 2015;19:208–215. doi: 10.1007/s10157-014-0962-5.

55. Foster M.C., Inker L.A., Hsu C.Y., Eckfeldt J.H., Levey A.S., Pavkov M.E., Myers B.D., Bennett P.H., Kimmel P.L., Vasan R.S., et al. Filtration markers as predictors of ESRD and mortality in Southwestern American Indians with type 2 diabetes. Am. J. Kidney Dis. 2015;66:75–83. doi: 10.1053/j.ajkd.2015.01.013.

56. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell. 2008;14:818–829. doi: 10.1016/j.devcel.2008.05.009.

57. Hu Q., Wu K., Pan W., Zeng Y., Hu K., Chen D., Huang X., Zhang Q. Intestinal flora alterations in patients with early chronic kidney disease: A case-control study among the Han population in southwestern China. J. Int. Med. Res. 2020;48:300060520926033. doi: 10.1177/0300060520926033.

58. Ikuma D., Hiromura K., Kajiyama H., Suwa J., Ikeuchi H., Sakairi T., Kaneko Y., Maeshima A., Kurosawa H., Hirayama Y., et al. The correlation of urinary podocytes and podocalyxin with histological features of lupus nephritis. Lupus. 2018;27:484–493. doi: 10.1177/0961203317734918.

59. Geng J., Qiu Y., Qin Z., Su B. The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients: A systematic review and Bayesian meta-analysis. J. Transl. Med. 2021;19:105. doi: 10.1186/s12967-021-02776-8.

60. Dudreuilh C., Fakhouri F., Vigneau C., Augusto J.F., Machet M.C., Rabot N., Chapal M., Charpy V., Barbet C., Büchler M., et al. The Presence of Renal IgG Deposits in Necrotizing Crescentic Glomerulonephritis Associated with ANCA Is Not Related to Worse Renal Clinical Outcomes. Kidney Dis. 2020;6:98–108. doi: 10.1159/000503969.

61. Mizdrak M., Filipović N., Vukojević K., Čapkun V., Mizdrak I., Durdov M.G. Prognostic value of connective tissue growth factor and c-Myb expression in IgA nephropathy and Henoch-Schönlein purpura-A pilot immunohistochemical study. Acta Histochem. 2020;122:151479. doi: 10.1016/j.acthis.2019.151479.

62. Bonventre J.V. Kidney injury molecule-1 (KIM-1): A urinary biomarker and much more. Nephrol. Dial. Transplant. 2009;24:3265–3268. doi: 10.1093/ndt/gfp010.

63. Singh S.S., Heijmans R., Meulen K.K.E., Lieverse A.G., Gornik O., Sijbrands E.J.G., Lauc G., van Hoek M. Association of the IgG N-glycome with the course of kidney function in type 2 diabetes. BMJ Open Diabetes Res. Care. 2020;8:e001026. doi: 10.1136/bmjdrc-2019-001026.